Autosomal Dominant Polycystic Kidney Disease Market Is Expected to Grow During the Forecast Period (2019-2032), DelveInsight | Key Companies – Tsuka Pharmaceutical, Sanofi, and Several Others

Autosomal Dominant Polycystic Kidney Disease Market Report gives readers a thorough assessment of key market drivers, restraints, prospects, opportunities, restraints, current trends, and technological and industrial breakthroughs that will influence market growth. The detailed market research, industry sector growth and development, and new product introductions covered in this report on the Autosomal Dominant Polycystic Kidney Disease Market are of great assistance to the important new commercial players joining the market.

 

This Autosomal Dominant Polycystic Kidney Disease Market report research conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The market driving factors, market overview, industry volume, and market share are also highlighted in this Autosomal Dominant Polycystic Kidney Disease Market report analysis.

 

Regions Covered in the Report

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

 

Click the link to get a Sample Copy of the Report before purchase- https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

 

Autosomal Dominant Polycystic Kidney Disease: An Overview

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder which causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations. Renal manifestations are produced by the progressive and continuous enlargement and proliferation of fluid-filled cysts, leading to enlargement of the kidney up to five times the normal volume in the years prior to the development of kidney failure. ADPKD may lead to development of end-stage renal disease (ESRD) and is the fourth most common renal disease requiring renal replacement therapy (RRT). The most common extra-renal manifestation is polycystic liver disease (PLD), which is more common in women than in men.

 

Key highlights of the Autosomal Dominant Polycystic Kidney Disease Market Report

According to Hospital-based nationwide survey in Japan, it has been found that the prevalence of ADPKD increased with age and reached a peak value of 261 per million population at the age group of 55-59 years. The probability of end-stage renal disease is at most 50% among ADPKD patients.
According to epidemiological review of ADPKD in the EU, a minimum prevalence of 2.41 and 3.89 per 10,000, and screening prevalence of 3.3 and 4.6 per 10,000 of ADPKD has been found in the German and British population-based studies. Whereas in registry-derived method, the minimum prevalence was 3.29 per 10,000, and if ADPKD screening was implemented in all European countries, the expected prevalence was 3.96 per 10 000
As per various epidemiological studies, the mutations in the PKD2 gene, particularly in women, typically have a less severe form of the disease than people with PKD1 mutations. The PKD2 mutation mostly appears in the adulthood.

 

Autosomal Dominant Polycystic Kidney Disease Epidemiology Insights

 A Large-scale cohort study of 541 Chinese ADPKD patients with a mean follow-up time of 14.3 months and mean age was 39.5 years demonstrated that three fourths of the patients had a family history of ADPKD. Nearly 75% of the patients had polycystic liver disease; 37% of the patients had chronic pain, and 23% had an episode of gross hematuria (Cheng Xue et al., 2016)

 

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation in the 7MM

Total Prevalent cases
Age-specific cases
Diagnosed and Treatable cases

 

Autosomal Dominant Polycystic Kidney Disease Treatment Market

Currently approved treatment options are mainly focused to slow the progression of ADPKD with reducing the size of the cyst. The therapeutic market size is accounted by therapies directed toward the management of kidney and non-kidney symptoms associated with the disease and it is based on prophylactic and supportive measures. Specifically, the treatment aims for blood pressure (BP) control and maximal inhibition of the renin-angiotensin-aldosterone system (RAAS) on progressive renal disease and cardiovascular manifestations in ADPKD. The kidney transplantation, frequent dialysis procedures along with nutritional supplements are also driving the market. The therapeutic market is driven by the increase in prevalent cases and is mainly driven by the patient pools of older ages.

 

Autosomal Dominant Polycystic Kidney Disease Market Insights

There is no cure for ADPKD and it not possible to stop cysts forming in the kidneys, however, a lot of research has been done in this space to find the ways to manage the disease. Majority of patients with ADPKD will eventually develop ESRD and require RRT. The progressiveness of this disease and its complications cause debilitating effects on health of patients and impose a significant burden, both economically and on the quality of life.

 

Autosomal Dominant Polycystic Kidney Disease Market Forecast

The research has helped now to understand the genetic and molecular basis of disease and the complex pathways in regulating the formation and development of cysts are being elucidated. New targeted therapies are available and can be tested in ADPKD, with the hope to find a cure or impact this disorder with novel therapeutic targets. Vigorous attempts have been done to develop medications to slow the

 

Make an Enquiry Before Buying- https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market

 

Table of Content

Key Insights
Executive Summary
Competitive Intelligence Analysis for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview
Patient Journey
Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Autosomal Dominant Polycystic Kidney Disease Unmet Needs
Key Endpoints of Autosomal Dominant Polycystic Kidney Disease Treatment
Autosomal Dominant Polycystic Kidney Disease Marketed Products
Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
Autosomal Dominant Polycystic Kidney Disease Seven Major Market Analysis
Attribute analysis
7MM: Autosomal Dominant Polycystic Kidney Disease Market Outlook
Access and Reimbursement Overview of Autosomal Dominant Polycystic Kidney Disease
KOL Views
Autosomal Dominant Polycystic Kidney Disease Market Drivers
Autosomal Dominant Polycystic Kidney Disease Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

 

Autosomal Dominant Polycystic Kidney Disease Market Report Highlights

In the coming years, the Autosomal Dominant Polycystic Kidney Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Autosomal Dominant Polycystic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Autosomal Dominant Polycystic Kidney Disease. The launch of emerging therapies will significantly impact the Autosomal Dominant Polycystic Kidney Disease market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Autosomal Dominant Polycystic Kidney Disease
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Autosomal Dominant Polycystic Kidney Disease market
To understand the future market competition in the Autosomal Dominant Polycystic Kidney Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Autosomal Dominant Polycystic Kidney Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the Autosomal Dominant Polycystic Kidney Disease market
To understand the future market competition in the Autosomal Dominant Polycystic Kidney Disease market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Generated by Feedzy
%d bloggers like this: